HCPCS Code Q5107: Injection, Bevacizumab-awwb, Biosimilar, (mvasi), 10 mg

Bevacizumab-awwb is FDA-approved and indicated for recurrent glioblastoma, but it is not indicated specifically for metastatic spine tumors. Its use would be tied to the primary cancer that has metastasized.

Bevacizumab-awwb is generally used in metastatic or recurrent disease, often in combination with chemotherapy (e.g., cervical, ovarian, colorectal cancers). It is not FDA-approved as routine adjuvant therapy following surgical resection, and soft tissue tumors are not listed indications. Use in these settings would be off-label and should follow payer policies.

When billing Q5107 for bevacizumab-awwb injection, accurate ICD-10 diagnosis codes that reflect tumor location (e.g., unspecified main bronchus) and behavior (e.g., uncertain or unspecified behavior) must be documented to establish medical necessity and support proper claim submission.